Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New HIV antibody combo heads into human safety tests

NCT ID NCT07217379

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times

Summary

This early-stage study tests whether two experimental antibodies (MGD014 and MGD020) are safe in people with HIV who are on standard antiretroviral therapy. Some participants will also take a drug to wake up hidden HIV, and others will pause their regular HIV meds for up to 8 weeks. The goal is to see if the antibodies can help control the virus, but this is not a cure—people will still need lifelong HIV treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kenya Medical Research Institute/Walter Reed Project

    NOT_YET_RECRUITING

    Kericho, Kenya

    Contact

  • Moi University Clinical Research Center

    NOT_YET_RECRUITING

    Eldoret, Kenya

    Contact

  • University of North Carolina

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

    Contact

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.